[Downloaded free from http://www.apjon.org on Tuesday, December 4, 2018, IP: 147.140.233.16]

Review Article

Clinical Framework for Quality Improvement
of Cancer Cachexia
Clara Granda‑Cameron1, Mary Pat Lynch2
Undergraduate Program, College of Nursing, Thomas Jefferson University, 2Abramson Cancer Center, Pennsylvania Hospital,
Philadelphia, PA, USA
1

Corresponding author: Clara Granda‑Cameron, DrNP, CRNP, APN-BC
College of Nursing, Thomas Jefferson University, Philadelphia, PA, USA
Tel: 215‑955‑5469; Fax: 2215‑955‑5674
E‑mail: clara.granda‑cameron@jefferson.edu
Received: March 27, 2018, Accepted: April 17, 2018

ABSTRACT
The objective of this article is to introduce the Clinical Framework
for Quality Improvement of Cancer Cachexia (Cachexia
Care Framework) as a tool to demonstrate the relevance of
integrating the clinical components of cancer cachexia and the
organizational strategies of a cancer institution on the quality
of patient care and delivery of services throughout the cancer
cachexia continuum. The data sources included peer-reviewed
literature relevant to cancer cachexia and quality cancer care,
and the authors’ expertise. The Cachexia Care Framework results
from a combination of the international consensus definition of
cancer cachexia, the Institute of Medicine report Ensuring Quality
Cancer Care, and the authors' experience with a cancer cachexia
clinic. This framework is proposed as a guidance for oncology
nurses and other healthcare providers to improve the quality
of care of cancer cachexia patients. Specifically, the framework
can be used by oncology nurses involved in the care of patients

diagnosed with cancer cachexia either in direct patient care,
administration, research, or education. Nurses can use the
framework in clinical practice to identify specific assessments
and interventions based on the cachexia stage of the patient;
in nursing administration, the framework offers a wide view of
potential errors that can happen and the opportunity to prevent
them; in nursing research, the framework illustrates the several
factors and processes that can impact patient outcomes; and
in nursing education, the framework outlines the elements
necessary to develop and implement a continuum education
curriculum to educate the workforce of oncology nurses, and in
the academic setting, an interprofessional curriculum to educate
nurses and many other healthcare disciplines.

Introduction

weight loss in patients with cancer is often overlooked
and rarely managed actively; it is an unmet need. Cancer

Cancer cachexia is a multidimensional syndrome that
affects up to half of all cancer patients.[1‑3] Involuntary
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cachexia can lead to significant functional impairment in
patients as well as psychological distress and poor quality
of life in patients and families if it is not addressed.[4,5] It
can also impact cancer treatment, linked to the risk of
poor response to treatment and shortened survival.[1] Team
approaches and holistic care to the management of cancer
cachexia have been proposed as a model of improving
patient care and outcomes.[6‑9]
The purpose of this article is to propose a clinical
framework for quality improvement of cancer cachexia
by focusing on potential gaps in care that prevents the
patient from accessing high‑quality care, throughout the
stages of cancer cachexia. The framework integrates new
definitions of cancer cachexia, its stages, and opportunities
for improvement. The authors have implemented a cancer
cachexia clinic over the past 10 years[9] and will translate
this experience into a framework for quality improvement,
using the international classification system developed by
Fearon et al.[2] and the Institute of Medicine (IOM) report
Ensuring Quality Cancer Care.[10] It is the authors’ hope
to define a novel approach to improve quality of care for
patients affected by cancer cachexia.

Cancer Cachexia
Cachexia is a serious and debilitating condition that
affects patients with cancer. Cachexia originates from the
Greek words kakos hexis meaning “bad condition” and
affects patients with cancer and other chronic diseases.[11]
A most recent international consensus was reached for the
definition of cancer cachexia: “a multifactorial syndrome
characterized by an ongoing loss of muscle mass (with or
without loss of fat mass) that cannot be fully reversed by
conventional nutritional support and leads to progressive
functional impairment.” [2] Cachexia remains a major
challenge in cancer because it affects 50%–80% of cancer
patients[12] and causes between 20% and 60% of cancer
deaths.[13] Cancer associated‑weight loss is present at the
time of diagnosis in 34% of patients with lung cancer and
gastrointestinal cancer including patients in Stage I (18%)
and Stage II (26%) disease and is also associated with
decreased survival.[14] The prevalence of cancer cachexia
ranges from 12% to 85% depending on the definition
used.[15] Based on the most recent consensus definition,
the prevalence of cancer cachexia is strongly related to
cancer type, being highest in lung cancer (83%), and
gastrointestinal cancers (62%) and lowest in hematologic
cancers (13%).[16]

Pathophysiology
The pathophysiology of cancer cachexia results
from both the tumor (primary cachexia) and the cancer
treatments (secondary cachexia).[17,18] In primary cancer
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cachexia, the tumor causes a systemic inflammatory
response that leads to multiple metabolic alterations
originating from tumor cells and activated immune
cells that release cytokines, chemokines, and other
inflammatory mediators.[17,19] Cachexia, also understood
as an energy‑wasting syndrome, is characterized by a
negative protein and energy balance led by a combination
of decreased food intake and abnormal metabolism.[17,11] In
secondary cancer cachexia, the cancer treatments (mainly
surgery, chemotherapy, and radiation therapy) have a
damaging impact on a patient’s nutritional intake through
the development of nutrition impact symptoms.[19,20] For
example, surgical resection of gastrointestinal organs
may cause dysphagia, gastroparesis, dumping syndrome,
or malabsorption; and both chemotherapy and radiation
therapy can induce anorexia, nausea, vomiting, mucositis,
hypogeusia, xerostomia, or fatigue.[19‑21]

Clinical classification
Cachexia is a clinical continuum of three stages:
precachexia, cachexia, and refractory cachexia [Table 1].[2]
In the precachexia stage, the patient experiences early clinical
and metabolic manifestations (i.e., anorexia and impaired
glucose tolerance) that may develop prior involuntary
weight loss. The possibility of advancing to the next stage
of cachexia depends on factors such as cancer type and
stage, occurrence of systemic inflammation, minimum
food intake, and poor response to cancer treatment.[2]
In the cachexia stage, patients experience weight loss of
more than 5% over the past 6 months; or a body mass
index (BMI) of <20 kg/m2 and weight loss of more than
2%; or sarcopenia and weight loss of more than 2%.[2]
Refractory cachexia results from preterminal advanced
cancer or quickly growing cancer, unresponsive to
treatments. This stage, related to increasing catabolism,
is associated with low‑performance status and a life
expectancy of <3 months.[2] The severity of depletion can
be categorized based on the speed of the continuous weight
Table 1: Classification of cancer cachexia
Stages

Criteria

Precachexia[2]

Weight loss ≤5%
Anorexia and metabolic change

Cachexia[2]

Weight loss >5% over the past 6 months (in the
absence of simple starvation)
or
BMI <20 and any degree of weight loss >2%
or
Appendicular skeletal muscle index consistent with
sarcopenia and any degree of weight loss >2%

Refractory
cachexia[2]

Variable degree of cachexia
Cancer disease both procatabolic and not responsive
to anticancer treatment
Low‑performance score <3 months expected survival

BMI: Body mass index
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loss in combination with the concurrent degree of depletion
of fat and body protein mass.[2] For example, a patient with
a BMI of 28 and a history of weight loss is more at risk if
he/she developed sarcopenia and less risk if his/her muscle
mass had no change.

Management: Assessment and interventions
The management of cancer cachexia includes clinical
assessment and multimodal interventions provided by an
interdisciplinary team. There is not a consensus agreement
about a specific tool to assess cachexia, but there is a
consensus about the domains that should be involved in
cancer cachexia assessment: anorexia or decreased food
intake, catabolic drivers, muscle mass and strength, and
functional and psychosocial effects.[20] Because of the lack
of cancer cachexia assessment tools, the most common
tools used are malnutrition assessment tools that help
to determine the degree of malnourishment and when
nutritional support should be initiated.[11]
Several authors have discussed the relevance of using
a multimodality approach to treat cancer cachexia. Del
Fabbro[20] proposed a multimodality treatment model that
includes pharmacologic and nonpharmacologic interventions
and nutrition support. Pharmacologic interventions target
the various metabolic mechanisms contributing to cancer
cachexia, for example, thalidomide, interleukin inhibitors,
fish oil, and nonsteroidal anti‑inflammatory drugs are
used to manage pro‑inflammatory cytokines; ghrelin,
megestrol, corticosteroids, and ghrelin mimetics are used
to control poor appetite; androgens and insulin address
endocrine dysfunction; and beta‑blockers manage the
elevated resting energy expenditure and weight. Progress in
the comprehension of the molecular biology of the brain,
immune system, and skeletal muscle have provided novel
targets for the treatment of cachexia.[19] There are a number
of clinical trials investigating pharmacologic agents targeted
to inflammatory processes during the precachexia and the
cachexia stages.[22] The nonpharmacologic interventions
include exercise, nutrition counseling, and control of
nutritional impact symptoms (NIS). Bruggeman et al.
recommend that oncologists make early referrals for timely
management of cachexia to palliative care specialists.[22]
Cancer cachexia is a complex syndrome and the goal of
the treatment is to fix the various broken pieces using an
interdisciplinary team approach.[6,23]

Clinical Framework for Quality
Care in Cancer Cachexia: An
Interdisciplinary Approach
Eight years ago, the authors proposed a cancer cachexia
clinic model to assess and manage the multiple symptoms

of cancer cachexia patients through an innovative all
in one interdisciplinary clinic, the Cancer Appetite and
Rehabilitation (CARE) Clinic model.[9] In the CARE
clinic model, the patients would be assessed and managed
by the entire team, all disciplines in one stop; instead
of having multiple appointments and being evaluated
by multiple disciplines at different visits. The clinic’s
interdisciplinary model included a physician, a nurse
practitioner, a nutritionist, a physical therapist, a speech
pathologist, and a clinic assistant. Although the CARE
clinic continues to run and manage cancer patients with
cachexia, the authors noticed that some patients were not
referred to the clinic and some patients did not return to the
clinic for follow‑up; therefore, they did not receive the care
they needed, in spite of having the cancer cachexia clinic
available to them. Adhering to the IOM report Delivering
High‑Quality Cancer Care[24] that focuses on the relevance
of high‑quality care along the entire trajectory of the cancer
care continuum, the authors decided to conduct a gap
analysis of the services offered to head‑and‑neck cancer
patients, including the CARE clinic, with the purpose of
identifying why some of these patients were lost in the
process of care. The gap analysis report was critical not only
to recognizing some flaws in care but also to learning that
the quality of care of cancer cachexia patients should go
beyond the care provided at the CARE clinic; it should cover
the total course of the cancer cachexia disease process.[25]
The authors propose a Clinical Framework for Quality
Care in Cancer Cachexia (Cachexia Care Framework)
to first, guide the care of cancer cachexia patients;
and second, to identify any potential failures in cancer
cachexia services that may hinder the quality of care
offered to this patient population [Figure 1]. The proposed
framework integrates the following: (a) the IOM report
Ensuring Quality Cancer Care that focuses on both, the
main points of cancer care (risk assessment, primary
prevention, screening, detection, diagnosis, treatment,
recurrence, surveillance, and end‑of‑life care), and on the
identification of failures in care in the transitions between
the points of care;[10] (b) the main elements of the cancer
cachexia definition, classification, and recommendations
described on the cancer cachexia international consensus;[2]
and (c) the CARE clinic model.[9] Many factors influence
cancer care environments and the performance of cancer
care institutions. The Cachexia Care Framework has three
main components, clinical, organizational, and outcomes.
The clinical component consists of the continuum of care
for cancer cachexia carried out by an interdisciplinary team
at each stage of the disease and at each point of cancer care
from risk assessment to end‑of‑life care. The organizational
component refers to the organizational performance
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Figure 1: Clinical framework for quality care in cancer cachexia: an interdisciplinary approach

with regard to identifying failures in cachexia care and
strategies to eradicate these failures that often happen
during transitions of care. The outcomes component assists
the interdisciplinary team and the cancer care institution
to measure if the care provided is effective. The outcomes
listed in Figure 1 are suggested, but more can be added
depending on the cancer institution’s needs.

Clinical component
There is an obvious change in the management of
cancer cachexia; while in the past, the focus was on
refractory cachexia, currently, it is on early detection and
management of cancer patients in the precachexia stage.[2]
The interdisciplinary cancer cachexia team plays a crucial
role in the evaluation of patients throughout the course
of their disease; they assess and manage cancer patients
who are at risk in developing cachexia or who are already
diagnosed with cachexia.

Precachexia stage
The precachexia stage includes risk assessment, early
detection, and diagnosis.
Risk assessment
Risk assessment of cachexia can be conducted by either
the nurse practitioner, the nurse navigator, or the nutritionist
of the team. Although about one‑third of cancer patients
present with high nutritional risk and have the potential to
develop cachexia, there are certain factors that may help
narrow down the list of cancer patients who need to be
assessed for cancer cachexia. Risk assessment consists of
the determination of certain factors that may alert cancer
care providers about the patients’ nutritional deterioration.
These factors include cancer type, cancer treatment,
performance status, and sarcopenia. Cancer patients
372

diagnosed with gastrointestinal cancers (pancreatic cancer,
gastric cancer, and esophageal cancer) and lung cancer
are at highest risk of developing cachexia.[20,26,27] Patients
undergoing cancer treatments that cause serious side effects
affecting their dietary intake may experience malnutrition
and cachexia, for example, patients with cancer of head
and neck receiving concurrent chemotherapy and radiation
therapy may develop severe stomatitis and dysgeusia that
may lead to secondary cachexia.[28,29] Poor performance
status can be identified in pretreatment stages; it is mostly
associated with early weight loss and inferior cancer
cachexia outcomes.[30] Sarcopenia, an age‑related condition
characterized by progressive loss of skeletal muscle mass
and strength, is developed independently of any disease
process. [31] It has a prevalence of 60% among adults
60‑year‑old and older and the muscle mass loss goes up to
15% per decade at 70 years of age and older.[32] While the
majority of sarcopenic patients do not develop cachexia, the
majority of cancer cachexia patients develop sarcopenia.[33]
Elderly patients who already have sarcopenia as a result of
their aging process and are diagnosed with cancer, are at
a higher risk to developing cachexia. The overlapping of
these both conditions can work synergistically to induce
increasing muscle mass loss.[33]

Early detection
Early detection of cachexia or precachexia can be
conducted by either one clinician or combination of
clinicians such as a nutritionist, a nurse navigator, a nurse
practitioner, and a physician. Early detection includes
assessment of high‑risk cancer patients by measuring weight
loss, BMI or muscle mass, and NIS.[2] There is not a specific
cancer cachexia assessment tool, but a few have been
suggested including the Edmonton Symptom Assessment
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Scale, the abridged patient‑generated subjective assessment,
the malnutrition‑screening tool, the mini‑nutritional
assessment, and the 12‑item Anorexia/Cachexia Scale
(A/CS‑12) among others.[11,20,34,35] Diagnosis of precachexia
is made based on the criteria described in the international
consensus described in Table 1.

Cachexia stage
The cachexia stage includes management and
surveillance. The management of cancer cachexia consists
of assessment and intervention.
Management
The Cachexia Care Framework recommends providing
the management of cancer cachexia through a specialized
cancer cachexia clinic. An example is the CARE clinic
described previously by the authors. The clinic is run by an
interdisciplinary team composed of a nurse practitioner, a
nutritionist, a physical therapist, a speech pathologist, and
a physician. A social worker, a chaplain, and a psychologist
may be called depending on the patient and family’s needs;
they may be available on the same day of the visit or on
another day. A comprehensive assessment is conducted on
those cancer patients who were previously screened and
diagnosed with either precachexia or cachexia.
Assessment
The assessment, an extended version of the initial
early detection screening, includes symptom assessment,
catabolic, muscle mass and strength, and functional and
psychosocial effects. [2] All symptoms are assessed, in
particular, those impacting nutrition such as anorexia,
nausea, vomiting, depression, gastroparesis, dysgeusia,
pain, diarrhea, and constipation.[2,20] The catabolic drivers
and systemic inflammation involved in cachexia can be
measured with the C‑reactive protein.[2] Furthermoe,
other comorbid deficiencies such as thyroid dysfunction,
hypogonadism, and Vitamin B12 and D deficiencies should
be investigated as they may contribute to fatigue, muscle
weakness, and anorexia.[2]
One of the main contributions of the international
consensus with regard to assessment of cancer cachexia
patients is the importance of measuring muscle mass
and strength. Determining body composition in a patient
with cachexia is a helpful tool because it facilitates
distinguishing between skeletal muscle and adipose
tissue.[33] Although there is not an agreement about the
assessment methods, the recommendation is to use
cross‑sectional imaging (computerized tomography [CT]
or magnetic resonance imaging [MRI]), dual‑energy
X‑ray imaging, anthropometry (mid‑arm muscle area),
and bioimpedance analysis.[2] CT or MRI of the lumbar
vertebral landmark (L3) has been validated as the best area

because in this region, skeletal muscle and adipose tissue
correspond to whole‑body tissue quantities.[36] Muscle
strength is usually assessed by the physical therapist using
the upper limb handgrip dynamometry.
Functional and psychosocial effects are assessed by any
member of the cachexia clinic. Psychosocial issues are
further explored by a psychologist, social worker, and/or
chaplain. The psychological effect of cachexia on cancer
patients was identified in a qualitative study reporting about
the many symbolic meanings of food on patients.[37] Eating
is a social activity with psychological relevance to people;
thus, anorexia and weight loss become distressing factors
to patients and their families.

Intervention
The therapeutic intervention for cancer cachexia is
accomplished by the entire interdisciplinary team. This
includes a wide‑ranging approach using pharmacologic
and nonpharmacologic therapies, as well as, nutritional
support to manage symptoms, reduce weight loss and
muscle wasting, and improve strength and stamina.[2,20]
The addition of exercise interventions is recommended to
increase lean muscle mass and improve functionality.[2,22]
However, more research, especially randomized clinical
trials are needed to support the relevance of exercise and
safety in cancer cachexia patients.[38]
Surveillance
Follow‑up care of patients is frequently done at the
cachexia clinic by the interdisciplinary team, but most
recently, the nurse navigator has played a significant role
in providing a close watch of these patients beyond the
cachexia clinic and during their transitions throughout
different health‑care settings.[39]
Refractory cachexia stage
Refractory cachexia is the result of a very advanced
and progressive cancer that is not responding to cancer
treatment. In this stage, patients’ performance status is
poor and cachexia is not reversible.[2] In contrast to previous
cachexia medication trials that allowed the participation
of terminally ill cancer patients, the current consensus
opposes these patients enrollment in this type of studies;
instead, palliative care and hospice care are recommended
in patients with refractory cachexia.[2] Artificial nutrition
and hydration are not encouraged in cancer patients at the
end of life, in their place, palliative care providing aggressive
symptom management and emotional support to the patient
and family should be offered. The reduction of oral intake
in the context of terminal disease can become a source of
distress to patients and their families, as they erroneously
believe that increased eating would increase survival.[40]
Educating patients and families that forcing the ingestion
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of food would actually cause indigestion, nausea, and
other symptoms would help them understand the natural
disease process. Futhermore, they can learn about providing
comfort measures at the end of life.

Organizational component
According to the report Ensuring Quality Cancer Care,
“quality care means providing patients with appropriate
services in a technically competent manner, with good
communication, shared decision‑making, and cultural
sensitivity.”[10] Excellent cancer cachexia care depends
on multiple factors related to the patient experiencing the
condition, the clinicians providing the care, and the cancer
institution supplying the infrastructure. Yet, most of the
accountability depends on the structure and the organized
support systems of the cancer institution and the clinicians
offering the care.[10] The Cachexia Care Framework’s
organizational strategies are discussed below.

Organizational strategies to reduce failures
There are numerous barriers to the implementation of
the Cachexia Care Framework. Organizational support
is essential to guarantee quality improvement and
implementation of recommendations for improvement in
cancer care. The role of nursing administration is crucial
to the success of this conceptual model and clinical
practice. Support from nursing leadership could include
advocating for funding through the budget process or
grant opportunities, to ensure that the clinic is sustainable
and functional. Identifying cost saving opportunities by
implementing early detection and a clinic model would
demonstrate the economic benefit of this model. Nursing
leaders within the cancer service line are in a unique
position to advocate for supportive care positions such as
nutritionists, speech therapists, physical therapists, and
palliative care nurses as essential cancer care team members.
Nursing informatics would be an important partner in
developing a cachexia screen that could be embedded in
the electronic medical record, ensuring that all cancer
patients are screened on diagnosis and at regular intervals
in their care. Nursing leadership could also advocate
for expanded inclusion in tumor conferences so that all
interdisciplinary team members are part of the discussion
about the treatment care plan. This would include allowing
those interdisciplinary team members time away from
direct care to attend such meetings. Nursing education
is also a key driver in ensuring that oncology nurses and
other interdisciplinary team members are aware of cancer
cachexia risk, diagnosis, screening, and treatment, allowing
nurses to play a key role in the treatment of these patients.
Cancer care is complex and often fragmented, and
although much progress has been made in developing
374

multidisciplinary tumor conferences, these are largely
focused on physicians rather than the entire interdisciplinary
team. Most cancer centers require that the patient attend
separate appointments for medical oncology, surgical
oncology, and radiation oncology. If supportive care
options are available, these are usually separate, additional
appointments as well. For a debilitated patient experiencing
cancer cachexia, this can be exhausting. Providing a
physical space where all providers can see the patient as a
team not only improves communication among the team
by allowing real‑time discussions and care planning but it
also decreases the physical exertion of the patient by having
the team come to him or her instead of the patient traveling
to multiple offices.
One potential solution to some of the barriers identified
is the role of the nurse navigator. According to the Oncology
Nursing Society, “an oncology nurse navigator (ONN)
(a) participates in the care of patients with a past, current,
or potential diagnosis of cancer, (b) assists patients with
cancer, families, and caregivers to overcome health‑care
system barriers, and (c) provides education and resources
to facilitate informed decision‑making and timely access to
quality health and psychosocial care throughout all phases
of the cancer continuum”.[41] A master’s prepared ONN
is in an ideal role to identify and implement screening for
cancer cachexia, for referring patients who are at risk or in
early stage cachexia for treatment and for following up with
patients to identify their individual barriers to screening,
treatment or follow‑up care, such as transportation, lack of
education, or cost. The nurse navigator can address those
barriers or refer to supportive care team members, to ensure
that patients at risk for or suffering from cancer cachexia
can access quality care. Nurse navigation is effective in
increasing patient satisfaction and decreasing barriers to
care.[42]
There are also financial and billing issues associated with
multidisciplinary care. Finding space can be challenging and
ensuring that all disciplines can bill from that space can be
impossible, due to Medicare and insurance guidelines that
ensure that care is being provided in appropriate settings for
that specialty. For example, in the CARE Clinic, colleagues
from physical therapy and speech therapy are unable to
bill for visits that occur outside their identified clinic. As a
result, a process was developed to cover the hourly cost of
the therapists through a grant and avoided billing the patient
for those hours. While this allowed implementation of the
CARE clinic, it is not sustainable.
Additional barriers include lack of consensus on a
cachexia screening tool that could be implemented for all
high‑risk patients at the start of treatment, the frequent
understaffing of supportive care staff such as nutrition and
palliative care in many cancer centers, the lack of provider
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and interdisciplinary team education about early diagnosis
of cancer cachexia, and failure to address patients who miss
appointments or are lost to follow‑up.

Outcomes component
The outcomes include medical outcomes and
patient‑centered outcomes. Medical outcomes are cachexia
status and mortality. Cachexia status should be determined at
the time of cancer diagnosis and after cachexia interventions
and cancer treatments have been implemented. The goal
is to reverse cancer cachexia and to cure cancer or keep
it in remission. Patient‑centered outcomes are symptom
management, patient’s function, patient’s quality of life,
and patient satisfaction. Measurement of these outcomes
helps the interdisciplinary team to evaluate the efficacy of
cancer cachexia interventions and offers the possibility for
improvement.

Nursing Implications
The Cachexia Care Framework, a knowledge translation
framework, is useful for oncology practice because it helps
organize and recognize the specific components, sequential
stages, and contextual factors needed to implement cancer
cachexia interventions effectively and attain the desired
outcomes.[43] The framework is helpful for any oncology
clinician, but for nurses, it highlights the nursing role
diversely as it expands into the dimensions of nursing
including clinical practice, administration, research, and
education. For nursing practice, the framework establishes
a congruent relationship between the cachexia stage and
the specific assessments and interventions recommended
at each clinical point in the process. For example, the
roles of the oncology nurse and the nurse navigator are
very important during risk assessment and early detection
in the precachexia stage, while the nurse practitioner
role is essential during management and surveillance of
cancer cachexia patients. For nursing administration, the
framework integrates the organizational nature of a cancer
cachexia program and the multiple operational aspects
necessary for the program to function efficiently. Nursing
leadership is greatly involved in looking at the potential
failures that can occur during the process of caring for the
cancer cachexia population and the developing of strategies
to either prevent errors or improve care in the health‑care
system. For nursing research, the framework provides
the structure to examine how variations in the cancer
cachexia components and the organizational characteristics
of the cancer institution may result in improved patient
outcomes and cancer cachexia services delivery. For nursing
education, the framework enables nurse educators to have
basic guidelines to construct a curriculum and determine
what knowledge and skills are needed to ensure that the

oncology nursing workforce is competent providing cancer
cachexia care. From the academic point of view, the
framework may assist the development and implementation
of interprofessional education and collaborative practice
curricula for nurses, medical students, speech‑language
pathologist students, and other health‑care students.[44]
Overall, the use of a framework for cancer cachexia care can
have a positive impact on improving the quality of life of
cancer patients and on the quality of the services delivered
to these patients.

Conclusion
Cancer cachexia is a common syndrome, affecting up to
half of all cancer patients and impacting function, response
to treatment, mortality, and quality of life. This paper has
proposed a clinical framework for quality improvement that
integrates new definitions of cancer cachexia and focuses
on gaps in care and opportunities for improvement. The
Cachexia Care Framework guides the care of the cachexia
patient and identifies any potential failures in services that
may hinder the quality of cachexia care. The goal of this
model is to improve care of the patient with cancer cachexia.
Adding nurse navigation to the interdisciplinary team can
address barriers to care, assess symptoms, provide patient
education, and ensure an extra layer of support during
transitions in care.
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